An interventional study of Consumption of FLAVIS in Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4 and Chronic Kidney Disease Stage 5, sponsored by Dr. Schär AG / SPA. Completed at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 238 studies in Renal Insufficiency, Chronic with a site in France — 55 open to participants now, 69 under way, 17 of them phase 3. Renal Insufficiency, Chronic · France.
Among the 238 studies in Renal Insufficiency, Chronic with a site in France, this one is the 77th largest by enrollment of the 165 interventional ones that give a count, is one of 22 that started in 2022, is one of 63 with no phase, and was the 176th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →55 of the 238 studies in Renal Insufficiency, Chronic with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in France, United States, Argentina and 24 more countries
Ages 18–99
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–80
AstraZeneca · Sites in France, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, China and 5 more countries
Ages 2–18
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
238 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 31 · Phase 3 62 · Phase 4 9
First in 2003; this study’s year is marked. 22 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 170 across the 165 interventional studies, 165 across the 73 observational. Of the 147 that completed or were terminated, 50 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 238 have an industry lead sponsor. The 10 most frequent:
Dr. Schär AG / SPA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Dr. Schär AG / SPA has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
20 of the studies in Renal Insufficiency, Chronic with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06692231Centre Hospitalier de VichyImpact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 238 studies in Renal Insufficiency, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein/ kg body weight/day is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Follow-up of the CKD patient according to current practice i.e. low protein diet.
Follow-up of the CKD patient according to the current practice i.e. low protein diet with the addition of of low-protein products (FLAVIS).
Other: Consumption of FLAVIS
Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
Effectiveness in terms of protein intake of a LPD with LP foods (FLAVIS products) compared to standard products (LPD without consumption of LP foods)
Maroni formula : (Measurement of urea in urine + (\[patient weight\]\*0.031))\*6.25
Time frame: 12 month
Protein intake during the 12 months follow-up
Maroni formula: (Measurement of urea in urine + (\[patient weight\]\*0.031))\*6.25
Time frame: 1 month, 3 month, 6 month and 9 month
Dietary adherence
3-day dietary record correlated to a 24-hour urine collection
Time frame: baseline, 1 month, 3 month, 6 month and 12 month
Dietary compliance for products under study
quantities consumed of FLAVIS products.
Time frame: monthly up to 12 months
Effects of the LPD on BMI
Weight and height will be combined to report BMI in kg/m\^2.
Time frame: baseline, 1 month, 3 month, 6 month and 12 month
Effects of the LPD on weight
Weight in kg
Time frame: baseline, 1 month, 3 month, 6 month and 12 month
Effects of the LPD on body composition: water
Water in litres
Time frame: baseline, 1 month, 3 month, 6 month and 12 month
Effects of the LPD on body composition: muscles
Muscles in Kg
Time frame: baseline, 1 month, 3 month, 6 month and 12 month
Effects of the LPD on body composition: body protein content
Body protein content in Kg
Time frame: baseline, 1 month, 3 month, 6 month and 12 month
Effects of the LPD on Blood
Blood Chemistry
Time frame: baseline, 1 month, 3 month, 6 month, 9 month and 12 month
Effects of the LPD on Urine
Urine Chemistry
Time frame: baseline, 1 month, 3 month, 6 month, 9 month and 12 month
Effects of the LPD on diabetic patient glycemic profile
Hb1Ac will be measured
Time frame: Baseline, 6 month and 12 month
Incidence of Adverse Events [Safety of the LPD]
Questioning and a clinical examination, biological analyses review
Time frame: 1 month, 3 month, 6 month, 9 month and 12 month
Incidence of Adverse Events [Safety of the LPD]
4-points Likert scale
Time frame: 3 month, 6 month and 12 month
Patient quality of life
SF-36 questionnaire score which from 0 to 100
Time frame: baseline, 3 month, 6 month and 12 month
Patient satisfaction with LPD
Auto-questionnaire with numerical scales, closed-ended questions and Likert scales
Time frame: 3 month, 6 month and 12 month
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2022 to primary completion in Jul 2026, 44 months.
Of 40 industry-sponsored interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 44 months is above that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Dr. Schär AG / SPA